scispace - formally typeset
A

Andrew M. Donson

Researcher at Anschutz Medical Campus

Publications -  139
Citations -  6568

Andrew M. Donson is an academic researcher from Anschutz Medical Campus. The author has contributed to research in topics: Medicine & Medulloblastoma. The author has an hindex of 34, co-authored 110 publications receiving 5175 citations. Previous affiliations of Andrew M. Donson include University of Melbourne & Boston Children's Hospital.

Papers
More filters
Journal ArticleDOI

Hotspot mutations in H3F3A and IDH1 define distinct epigenetic and biological subgroups of glioblastoma.

Dominik Sturm, +82 more
- 16 Oct 2012 - 
TL;DR: It is demonstrated that each H3F3A mutation defines an epigenetic subgroup of GBM with a distinct global methylation pattern, and that they are mutually exclusive with IDH1 mutations, which characterize a third mutation-defined subgroup.
Journal ArticleDOI

Molecular Classification of Ependymal Tumors across All CNS Compartments, Histopathological Grades, and Age Groups

Kristian W. Pajtler, +61 more
- 11 May 2015 - 
TL;DR: The molecular classification proposed herein outperforms the current histopathological classification and thus might serve as a basis for the next World Health Organization classification of CNS tumors.
Journal ArticleDOI

Genomic analysis of diffuse intrinsic pontine gliomas identifies three molecular subgroups and recurrent activating ACVR1 mutations

TL;DR: This work integrated whole-genome sequencing with methylation, expression and copy number profiling, discovering that DIPGs comprise three molecularly distinct subgroups (H3-K27M, silent and MYCN) and uncovering a new recurrent activating mutation affecting the activin receptor gene ACVR1 in 20% of DIPG.
Journal ArticleDOI

Autophagy inhibition improves chemosensitivity in BRAF(V600E) brain tumors.

TL;DR: In this article, the authors found that mutant cells with BRAFV600E exhibited high rates of induced autophagy, are sensitive to pharmacologic and genetic autophagation inhibition, and display synergy when combined with the Raf inhibitor vemurafenib or standard chemotherapeutics.
Journal ArticleDOI

MGMT promoter methylation correlates with survival benefit and sensitivity to temozolomide in pediatric glioblastoma

TL;DR: This data indicates that methylation of the DNA‐repair gene O6‐methylguanine‐DNA methyltransferase causes gene silencing in children with GBM and its relationship to survival and temozolomide sensitivity is unclear.